BiologicalDrug
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F clinical trials
Also written AZD0120 and GC012F.
- studies test it
- 28
- open now
- 20
- in phase 3
- 3
- first study started
- 2020
Keep track of what changes. Save the Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2025 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 9 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 12
- Phase 1
- 13
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 16
AstraZeneca (8) · Shanghai Changzheng Hospital (5) · Gracell Biotechnologies (Shanghai) Co., Ltd. (3) · Daishi Tian (3) · Zhejiang University (2) · Qiong Fu (1) · Chongbo Zhao (1) · Alexion Pharmaceuticals, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F is read from its arms, and is right about nine times in ten.
Testing it · 28
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as AZD0120
- AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)RecruitingPhase 1/2AstraZenecaNCT05850234Written as AZD0120
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as AZD0120
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)RecruitingPhase 1AstraZenecaNCT07073547Written as AZD0120
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingPhase 1/2AstraZenecaNCT06897930Written as AZD0120
- An Open-label Study of AZD0120 in Adults With Multiple SclerosisRecruitingPhase 1AstraZenecaNCT07224373Written as AZD0120 - Regimen 1
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingPhase 3AstraZenecaNCT07764978Written as AZD0120
- A Study of AZD0120 in Autoimmune DiseasesRecruitingPhase 1AstraZenecaNCT07295847Written as AZD0120
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisRecruitingPhase 1Gracell Biotechnologies (Shanghai) Co., Ltd.NCT07250269Written as GC012F Injection
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.RecruitingPhase 1/2Alexion Pharmaceuticals, Inc.NCT07081646Written as AZD0120
- Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) PatientsRecruitingEarly Phase 1RenJi HospitalNCT05858684Written as GC012F injection
- This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple SclerosisRecruitingEarly Phase 1Daishi TianNCT07303790Written as GC012F CAR-T Cell Injection
- CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant ParticipantsRecruitingEarly Phase 1Tongji HospitalNCT07350837Written as AZD0120
- A Study of GC012F in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2Gracell Biotechnologies (Shanghai) Co., Ltd.NCT06235229Written as GC012F
- GC012F Injection in Refractory Idiopathic Inflammatory MyopathyRecruitingEarly Phase 1Daishi TianNCT07086404Written as GC012F Injection infusion
- GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)RecruitingEarly Phase 1Daishi TianNCT07058298Written as GC012F injection
- GC012F in Patients With Autoimmune DiseasesNot yet recruitingEarly Phase 1Qiong FuNCT07072884Written as GC012F injection
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingPhase 1Chongbo ZhaoNCT06759948Written as GC012F injection
- Study of FasT CAR-T GC012F Injection NDMM PatientsRecruitingEarly Phase 1Shanghai Changzheng HospitalNCT05840107Written as GC012F injection
- Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus ErythematosusRecruitingPhase 1Zhejiang UniversityNCT05846347Written as GC012F injection
See all 28 studies that test Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F →